SCHEMBL26665758

SCHEMBL26665758

CC(C)OC(=O)c1ccn2c(C(=O)c3ccc(Cl)cc3)cc(C(=O)O)c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 11/20 0.59
▸ FNTB P49356 11/20 0.59
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ NPSR1 Q6W5P4 3/20 0.38
▸ HPGD P15428 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ ABCB11 O95342 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26665757 0.90 FNTA (0.58) FNTAFNTBCA12CA1CA2
SCHEMBL26665760 0.90 FNTA (0.64) FNTAFNTBCA12CA1CA2
SCHEMBL26665770 0.89 FNTA (0.51) FNTAFNTBCA12CA1CA2
SCHEMBL26665763 0.89 FNTA (0.59) FNTAFNTBCA12CA1CA2
SCHEMBL26829996 0.87 ALDH1A1 (0.52) FNTAFNTBNPC1RAB9ANPSR1
SCHEMBL26665754 0.86 FNTA (0.48) FNTAFNTBCA12CA1CA2
SCHEMBL26665759 0.82 FNTA (0.46) FNTAFNTBCA12CA1CA2
SCHEMBL26830001 0.78 ALDH1A1 (0.54) FNTAFNTBCA12CA1CA2
SCHEMBL26829993 0.78 ALDH1A1 (0.57) FNTAFNTBNPC1RAB9ANPSR1
SCHEMBL26829999 0.77 ALDH1A1 (0.52) FNTAFNTBNPSR1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11981673-B1 7-isopropyl 1,2-dimethyl 3-(substituted benzoyl)indolizine-1,2,7 tricarboxylates as adenosine receptor active compounds King Faisal University (SA) 2024-05-14 — — US claimed
US-11807640-B1 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as anti-tubercular agents King Faisal University (SA) 2023-11-07 — — US claimed
US-11981674-B1 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as larvicidal agents King Faisal University (SA) 2024-05-14 — — US disclosed
US-11981673-B1 7-isopropyl 1,2-dimethyl 3-(substituted benzoyl)indolizine-1,2,7 tricarboxylates as adenosine receptor active compounds King Faisal University (SA) 2024-05-14 — — US disclosed
US-11807640-B1 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as anti-tubercular agents King Faisal University (SA) 2023-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11981674-B1 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as larvicidal agents CASP7, CASP3, CASP2 FNTA 2187/4885FNTB 2405/4885CA12 4810/4885
US-11981673-B1 7-isopropyl 1,2-dimethyl 3-(substituted benzoyl)indolizine-1,2,7 tricarboxylates as adenosine receptor active compounds ADORA3, ADORA2A, ADORA1 FNTA 3213/4885FNTB 2090/4885CA12 4773/4885
US-11807640-B1 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as anti-tubercular agents IRF3, TBK1, TBKBP1 FNTA 1843/4885FNTB 508/4885CA12 4768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback